To avoid deleterious effects to the eyes, we evaluated an antisense oligonucleotide (ASO) that specifically knocks down MerTK expression on tumor growth in combination with localized radiation (XRT) and αPD1 in a mouse model of anti-PD1-resistant cancer (Fig. 1A). This evidence concerns the gene MERTK and neoplasm.